AMENDMENTS TO THE CLAIMS

What is claimed is:

1. (Currently Amended) A compound of Formula (I), or a pharmaceutically acceptable salt thereof,

wherein the compound of Formula (I) is:

$$R^1$$
 T_3 R^2

(I)

wherein:

$$R^{1}$$
 is K' or $-(C(R_{e})(R_{f}))_{aa}-T_{3}-A$;

$$(C(R_e)(R_f))_{aa}$$

$$(C(R_e)(R_f))_{aa}$$

$$CH$$

$$T_3$$

$$K$$

•

Docket No.: 0102258.00368US2

A is a hydrogen, K, K',

Application No. 10/581,340 Amendment dated March 20, 2009

Reply to Office Action of December 23, 2008

Docket No.: 0102258.00368US2

R_b is a hydrogen, a lower alkyl group or -COCH₃;

R_c is a hydrogen or a lower alkyl group;

D is a hydrogen, V₃, K or K';

Z is an oxo, an oxime, a hydrozone, =N-O-A, -N-(OA)- R_{82} , =N-N-(A)(R_{82}) or =N-(R_{82});

R₈₂ is a hydrogen, K, K', an alkyl group, an aryl group, an alkylsulfonyl group, an arylsulfonyl group, a carboxylic ester, an alkylcarbonyl group, an arylcarbonyl group, a carboxamido group, an alkoxyalkyl group or an alkoxyaryl group;

 $\label{eq:Kis-Wa-Eb-(C(Re)(Rf))p1-Ec-(C(Re)(Rf))_x-Wd-(C(Re)(Rf))_y-Wi-Ej-Wg-(C(Re)(Rf))_z-(U_3)_{bb}-V_3;$

 $K' \ is \ -W_a - E_b - (C(R_e)(R_f))_{p1} - E_c - (C(R_e)(R_f))_x - W_d - (C(R_e)(R_f))_y - W_i - E_j - W_g - (C(R_e)(R_f))_z - R_e;$ $V_3 \ is \ -NO, \ -NO_2 \ or$

 U_3 is an oxygen, sulfur or $-N(R_a)R_i$;

a, b, c, d, g, i and j are each independently an integer from 0 to 3;

aa is an integer from 0 to 5;

bb is an integer 0 or 1;

p₁, x, y and z are each independently an integer from 0 to 10;


W at each occurrence is independently -C(O)-, -C(S)-, -T₃-, -(C(R_e)(R_f))_h-, an alkyl group, an aryl group, a heterocyclic ring, an arylheterocyclic ring, -(CH₂CH₂O)_{q1}- or a heterocyclic nitric oxide donor;

E at each occurrence is independently $-T_3$ -, an alkyl group, an aryl group,

Docket No.: 0102258.00368US2

- $(C(R_e)(R_f))_h$ -, a heterocyclic ring, an arylheterocyclic ring, - $(CH_2CH_2O)_{q1}$ - or $Y_{3;}$

Y₃ is:



T is a $-S(O)_o$; a carbonyl or a covalent bond;

o is an integer from 0 to 2;

 R_j and R_k are independently selected from an alkyl group, an aryl group, or R_j and R_k taken together with the nitrogen atom to which they are attached are a heterocylic ring;

T₃ at each occurrence is independently a covalent bond, a carbonyl, an oxygen,

 $-S(O)_o$ - or $-N(R_a)R_i$;

h is an integer form 1 to 10;

 q_1 is an integer from 1 to 5;

R_e and R_f are each independently a hydrogen, an alkyl, a cycloalkoxy, a halogen, a hydroxy, an hydroxyalkyl, an alkoxyalkyl, an arylheterocyclic ring, an alkylaryl, an alkylcycloalkyl, an alkylheterocyclic ring, a cycloalkylalkyl, a cycloalkylthio, an arylalklythio, an arylalklythioalkyl, an

alkylthioalkyl a cycloalkenyl, an heterocyclicalkyl, an alkoxy, a haloalkoxy, an amino, an alkylamino, a dialkylamino, an arylamino, a diarylamino, an alkylarylamino, an alkoxyhaloalkyl, a sulfonic acid, a sulfonic ester, an alkylsulfonic acid, an arylsulfonic acid, an arylalkoxy, an alkylthio, an arylthio, a cyano an aminoalkyl, an aminoaryl, an aryl, an arylalkyl, an alkylaryl, a carboxamido, a alkylcarboxamido, an arylcarboxamido, an amidyl, a carboxyl, a carbamoyl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarbonyl, an arylcarbonyl, an ester, a carboxylic ester, an alkylcarboxylic ester, an arylcarboxylic ester, a sulfonamido, an alkylsulfonamido, an alkylsulfonyl, an alkylsulfonyloxy, an arylsulfonyl, arylsulphonyloxy, a sulfonic ester, an alkyl ester, an aryl ester, a urea, a phosphoryl, a nitro, -(UB_{3B})B_{bbB}-VB_{3B}, -C(RB_{eB})(RB_{fB})B_{kB}-(UB_{3B})B_{bbB}-VB_{3B}, or RB_{eB} and RB_{fB} taken together with the carbons to which they are attached form a carbonyl, a methanthial, a heterocyclic ring, a cycloalkyl group, an aryl group, an oxime, a hydrazone or a bridged cycloalkyl group;

k is an integer from 1 to 3;

RB_{aB} is a lone pair of electrons, a hydrogen or an alkyl group;

 RB_{iB} is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an arylcarboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylsulfinyl, an alkylsulfinyl, an alkylsulfonyloxy, an arylsulfinyl, an arylsulfonyl, arylsulphonyloxy, a sulfonamido, a carboxamido, a carboxylic ester, an aminoalkyl, an aminoaryl, - CHB_{2B} -C- $((UB_{3B})B_{bbB}$ - $VB_{3B})(RB_{eB})(RB_{fB})$, a bond to an adjacent atom creating a double bond to that atom,

-(NB_{2B}OB_{2B}-)P^{-P}•MB_{1PB}^{+P}, wherein MB_{1PB}^{+P} is an organic or inorganic cation;

with the proviso that the pyruvate compound of Formula (I) must contain at least only one nitric oxide releasing group linked to the pyruvate compound through an oxygen atom, a nitrogen atom or a sulfur atom:

and with the further proviso that the compounds of Formula (I) do not include L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[4-(1,2-dioxopropyl)-1-piperazinyl]-, 5-nitrate and L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[4-(1,2-dioxopropyl)-1-piperazinyl]-, 5-nitrate, monohydrochloride.

2. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

3. (Original) The compound of claim 1, wherein the nitric oxide releasing group is a nitro group, a nitroso group, a furoxan, a sydnonimine, an oxatriazole-5-one and/or an oxatriazole-5-imine.

Docket No.: 0102258.00368US2

4. (Currently Amended) The compound of claim 1, wherein the compound of Formula (II);

wherein the compound of Formula (III) is:

$$H_3C$$
 T
 Rm
 Rm

wherein

R_m-R_n taken together can be a hydrogen atom; or

R_m is:

(i) a covalent bond;

(ii) $-C((R_e)(R_f))_{2-5}$;

(iii) $-C((R_e)(R_f))_{2-5}-T-';$

(iv) $-C((R_e)(R_f))_{2-5}$ -T'-C(O)-;

(v) a heterocyclic ring; or

(vi) a heterocyclic ring-C(O)-;

R_n is:

a hydrogen or:

Application No. 10/581,340 Docket No.: 0102258.00368US2 Amendment dated March 20, 2009

Reply to Office Action of December 23, 2008

$$(1) \qquad \qquad (2) \qquad \qquad (4) \qquad \qquad (4) \qquad \qquad (5) \qquad (6) \qquad \qquad (6) \qquad \qquad (7) \qquad \qquad (8) \qquad \qquad (9) \qquad$$

wherein:

T' is oxygen, sulfur or NR₆;

R₆ is a hydrogen, a lower alkyl group, an aryl group;

Re and Rf are as defined herein; and

with the proviso that the compounds of Formula (III) must contain-at least only one nitric oxide releasing group linked to the pyruvate compound through an oxygen atom, a nitrogen atom or a sulfur atom.

5 - 10. (Cancelled).

Application No. 10/581,340 Amendment dated March 20, 2009

Reply to Office Action of December 23, 2008

11. (Original) The composition of claim 2, further comprising (i) at least one therapeutic agent; (ii) at least one nitric oxide donor compound; or (iii) at least one therapeutic agent and at least one nitric oxide donor compound.

Docket No.: 0102258.00368US2

- 12. (Original) The composition of claim 11, wherein the therapeutic agent is an aldosterone antagonist, an alpha-adrenergic receptor antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, an antidiabetic compound, an anti-hyperlipidemic compound, an antioxidant, an antithrombotic and vasodilator compound, a β-adrenergic antagonist, a calcium channel blocker, a digitalis, a diuretic, an endothelin antagonist, a hydralazine compound, a H₂ receptor antagonist, a neutral endopeptidase inhibitor, a nonsteroidal antiinflammatory compound, a phosphodiesterase inhibitor, a potassium channel blocker, a platelet reducing agent, a proton pump inhibitor, a renin inhibitor, a selective cyclooxygenase-2 inhibitor, or a combination of two or more thereof.
- 13. (Original) The composition of claim 12, wherein the therapeutic agent is at least one compound selected from the group consisting of an aldosterone antagonist, an angiotensin II antagonist, an angiotensin-converting enzyme inhibitor, a β -adrenergic antagonist, a diuretic and a hydralazine compound.
- 14. (Original) The composition of claim 13, wherein the aldosterone antagonist is eplerenone or spironolactone; the angiotensin II antagonist is candesartan cilexetil, eprosartan mesylate, irbesartan, losartan potassium, medoxomil, telmisartan, trandolapril, trandolaprilat or valsartan; the angiotensin-converting enzyme inhibitor is benazepril hydrochloride, captopril, enalapril maleate, fosinopril sodium, lisinopril, moexipril hydrochloride, quinapril hydrochloride; the β-adrenergic antagonist is bisoprolol fumarate, carvedilol, metoprolol tartrate, propranolol hydrochloride or timolol maleate; the diuretic is amiloride hydrochloride, chlorthalidone, hydrochlorothiazide or triamterene; and the hydralazine compound is hydralazine hydrochloride.
- 15. (Original) The composition of claim 11, wherein the nitric oxide donor compound is selected from the group consisting of a S-nitrosothiol, a nitrite, a nitrate, a S-nitrothiol, a sydnonimine, a NONOate, a N-nitrosoamine, a N-hydroxyl nitrosamine, a nitrosimine, a diazetine dioxide, an oxatriazole 5-imine, an oxatriazole-5-one, an oxime, a hydroxylamine, a N-hydroxyguanidine, a hydroxyurea and/or a furoxan.

- 16 18. (Cancelled).
- 19. (Original) A kit comprising at least one compound of claim 1.
- 20. (Currently Amended) A compound selected from the group consisting of:

Docket No.: 0102258.00368US2

- 1-[4-(nitrooxy)piperidyl]propane-1,2-dione;
- N-[3-(nitrooxy)propyl]-2-oxopropanamide;
- N-[2,2-dimethyl-3-(nitrooxy)propyl]-2-oxopropanamide;
- N-[(1S)-2-(nitrooxy)-1-phenylethyl]-2-oxopropanamide;
- N-[(1S)-2-(Nnitrooxy)-1-benzylethyl]-2-oxopropanamide;
- N-[(5-hydroxy-4-methyl(1,2,5-oxadiazol-3-yl))methyl]-N-methyl-2-oxopropanamide;
- (4R)-2-methyl-5-(nitrooxy)-N-(2-oxo(3-3,4,5-trihydrothienyl))-4-phenyl-3-azapent-2-enamide;
- {3-[(nitrooxy)methyl]phenyl}methyl 2-oxopropanoate;
- (4-(nitrooxy)piperidyl)methyl-2-oxopropanoate;
- 2-(4-(nitrooxy)piperidyl)ethyl-2-oxopropanoate;
- 3-(4-(nitrooxy)piperidyl)propyl-2-oxopropanoate;
- 1-(4-(nitrooxy)piperidyl)propane-1,2-dione;

(2R)-2,3-bis(nitrooxy)propyl-2-oxopropanoate;

- (4-(2-(nitrooxy)ethyl)phenyl)methyl-2-oxopropanoate;
- (4-((nitrooxy)methyl)piperzinyl)methyl-2-oxopropanoate;
- 2-(4-((nitrooxy)methyl)piperzinyl)ethyl-2-oxopropanoate;
- 3-(4-((nitrooxy)methyl)piperzinyl)propyl-2-oxopropanoate;
- (4-(2-(nitrooxy)ethyl)piperzinyl)methyl-2-oxopropanoate;
- 2-(4-(2-(nitrooxy)ethyl)piperzinyl)ethyl-2-oxopropanoate;
- 3-(4-(2-(nitrooxy)ethyl)piperzinyl)propyl-2-oxopropanoate;
- (4-(3-(nitrooxy)propyl)piperzinyl)methyl-2-oxopropanoate;
- 2-(4-(3-(nitrooxy)propyl)piperzinyl)ethyl-2-oxopropanoate;
- 3-(4-(3-(nitrooxy)propyl)piperzinyl)propyl-2-oxopropanoate;
- 1-(2-((nitrooxy)methyl)piperidyl)propane-1,2-dione;
- 1-(3-((nitrooxy)methyl)piperidyl)propane-1,2-dione;
- 1-(4-((nitrooxy)methyl)piperidyl)propane-1,2-dione;

methyl (2R)-2-amino-3-((3-((2-(2-(nitrooxy)ethoxy)ethyl)amino)-2,3-dioxopropyl)thio) propanoate;

4-(N-((1R)-1-(methoxycarbonyl)-2-(2-(N-(2-(nitrooxy)ethoxy)ethyl)carbamoyl)-2-

oxoethylthio)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

2-(4-(2-(nitrooxy)ethoxy)phenoxy)ethyl 3-((2R)-2-amino-2-(methoxycarbonyl)ethylthio)-2-oxopropanoate;

4-(N-((1R)-1-(methoxycarbonyl)-2-(2-((2-(4-(2-(nitrooxy)ethoxy)phenoxy)ethyl)oxycarbonyl)-2-oxoethylthio)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-((1-((nitrooxy)methyl)benzyl)oxy)-2,3-dioxopropyl)thio) propanoate;

4-(N-((1R)-1-(methoxycarbonyl)-2-(2-(((3-((nitrooxy)methyl)phenyl)methyl)oxycarbonyl)-2-oxoethylthio)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2*R*)-2-amino-3-((3-((4-((nitrooxy)methyl)benzyl)oxy)-2,3-dioxopropyl)thio) propanoate;

4-(N-((1R)-1-(methoxycarbonyl)-2-(2-(((4-((nitrooxy)methyl)phenyl)methyl)oxycarbonyl)-2-oxoethylthio)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-((3-(nitrooxy)propyl)amino)-2,3-dioxopropyl)thio)propanoate;

- 3-(nitrooxy)propyl 2-oxopropanoate;
- 3-(pyruvoylamino)propyl nitrate;
- 2,2-dimethyl-3-(nitrooxy)propyl 2-oxopropanoate;
- 2,2-dimethyl-3-(pyruvoylamino)propyl nitrate;
- 3-(nitrooxy)-2-[(nitrooxy)methyl]propyl 2-oxopropanoate;
- 2-(nitrooxy)-1-[(nitrooxy)methyl]ethyl 2-oxopropanoate;
- 2-(pyruvoylamino)propane-1,3-diyl dinitrate;
- 3,5-bis[(nitrooxy)methyl]benzyl 2-oxopropanoate;
- 2-methyl-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl 2-oxopropanoate;
- 3-(nitrooxy)-2,2-bis[(nitrooxy)methyl]propyl 2-oxopropanoate;
- 2-{4-[2-(nitrooxy)ethoxy]phenoxy}ethyl 2-oxopropanoate;
- ${\color{blue}2-nitro-3-(nitrooxy)-2-[(nitrooxy)methyl]propyl~2-oxopropanoate;}\\$
- 2-[2-(pyruvoylamino)ethoxy]ethyl nitrate;
- 3-[(nitrooxy)methyl]benzyl 2-oxopropanoate;
- 4-[(nitrooxy)methyl]benzyl 2-oxopropanoate;

- (2S) 2-amino-5-[3-(nitrooxy) 2-[(nitrooxy)methyl] 2-(pyruvoylamino)propoxy] 5-oxopentanoic acid;
- (2S)-2-amino-5-({2-(nitrooxy)-1-[(nitrooxy)methyl]-1-[(pyruvoyloxy)methyl]ethyl}amino)-5-oxopentanoic acid;
- (2S)-2-amino-5-{3-(nitrooxy)-2-[(pyruvoyloxy)methyl]propoxy}-5-oxopentanoic acid;
- (2S)-2-amino-5-{2-methyl-3-(nitrooxy)-2-[(pyruvoyloxy)methyl]propoxy}-5-oxopentanoic acid;
- (2S) 2-amino-5-{3-(nitrooxy) 2-[(nitrooxy)methyl]-2-[(pyruvoyloxy)methyl]propoxy}-5-oxopentanoic acid;
- (2S)-2-amino-5-{2-nitro-3-(nitrooxy)-2-[(pyruvoyloxy)methyl]propoxy}-5-oxopentanoic acid;
- (2S)-2-amino-5-[3-(nitrooxy)-2-(pyruvoylamino)propoxy]-5-oxopentanoic acid;
- (2S)-2-amino-5-({3-[(nitrooxy)methyl]-5-[(pyruvoyloxy)methyl]benzyl}oxy)-5-oxopentanoic acid;
- (2S)-2-amino-5-[3-(nitrooxy)-2-(pyruvoyloxy)propoxy]-5-oxopentanoic acid;
- (2S)-2-amino-5-{2-(nitrooxy)-1-[(pyruvoyloxy)methyl]ethoxy}-5-oxopentanoic acid;
- (2S)-2-amino-5-({2-(nitrooxy)-1-[(pyruvoyloxy)methyl]ethyl}amino)-5-oxopentanoic acid;
- 4-(N-((1R)-1-(methoxycarbonyl)-2-(2-(N-(3-(nitrooxy)propyl)carbamoyl)-2-

oxoethylthio)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2*R*)-2-amino-3-((3-((2,2-dimethyl-3-(nitrooxy)propyl)amino)-2,3-dioxopropyl)thio) propanoate;

4-(N-((1R)-2-(2-(N-(2,2-dimethyl-3-(nitrooxy)propyl)carbamoyl)-2-oxoethylthio)-1-

(methoxycarbonyl)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-((2-(nitrooxy)-1-((nitrooxy)methyl)ethyl)amino)-2,3-dioxopropyl) thio)propanoate;

4-(N-((1R) 1-(methoxycarbonyl) 2-(2-(N-(2-(nitrooxy) 1-((nitrooxy)methyl)ethyl)carbamoyl) 2-oxoethylthio)ethyl)carbamoyl)(2S) 2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-(a-(nitrooxy)-2,2-bis((nitrooxy)methyl)propoxy)-2,3-dioxopropyl) thio)propanoate;

4-(N-((1R) 2-(2-((2,2-bis((nitrooxy)methyl) 3-(nitrooxy)propyl)oxycarbonyl) 2-oxoethylthio) 1-(methoxycarbonyl)ethyl)carbamoyl)(2S) 2-aminobutanoic acid;

methyl (2R) 2-amino-3-((3-(2-methyl-3 (nitrooxy) 2 ((nitrooxy)methyl)propoxy) 2,3-dioxopropyl) thio)propanoate;

4 (N ((1R) 1 (methoxycarbonyl) 2 (2 ((2 methyl 3 (nitrooxy) 2 ((nitrooxy)methyl)propyl) oxycarbonyl) 2 oxoethylthio)ethyl)carbamoyl)(2S) 2 aminobutanoic acid; methyl (2R) 2 amino 3 ((3 (2 nitro 3 (nitrooxy) - 2 ((nitrooxy)methyl)propoxy) - 2,3 dioxopropyl)thio)propanoate;

4-(N-((1R) 1-(methoxycarbonyl) 2-(2-((2-nitro-3-(nitrooxy)-2-((nitrooxy)methyl)propyl) oxycarbonyl) 2-oxoethylthio)ethyl)carbamoyl)(2S) 2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-(3-(nitrooxy)propoxy)-2,3-dioxopropyl)thio)propanoate;

4-(N-((1R)-1-(methoxycarbonyl)-2-(2-((3-(nitrooxy)propyl)oxycarbonyl)-2-oxoethylthio) ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

 $methyl\ (2R)-2-amino-3-((3-(2,2-dimethyl-3-(nitrooxy)propoxy)-2,3-dioxopropyl) thio)\ propanoate;$

4-(N-((1R)-2-(2-((2,2-dimethyl-3-(nitrooxy)propyl)oxycarbonyl)-2-oxoethylthio)-1-

(methoxycarbonyl)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2R) 2-amino-3-((3-(3-(nitrooxy)-2-((nitrooxy)methyl)propoxy)-2,3-dioxopropyl) thio)propanoate;

4-(N-((1R) 1-(methoxycarbonyl) 2-(2-((3-(nitrooxy) 2-((nitrooxy)methyl)propyl)oxycarbonyl) 2-oxoethylthio)ethyl)carbamoyl)(2S) 2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-(2-(nitrooxy)-1-((nitrooxy)methyl)ethoxy)-2,3-dioxopropyl)thio) propanoate;

4-(N-((1R)-1-(methoxycarbonyl)-2-(2-((2-(nitrooxy)-1-((nitrooxy)methyl)ethyl)oxycarbonyl)-2-oxoethylthio)ethyl)carbamoyl)(2S)-2-aminobutanoic acid;

methyl (2R)-2-amino-3-((3-((3,5-bis((nitrooxy)methyl)benzyl)oxy)-2,3-dioxopropyl)thio) propanoate;

4-(N-((1R) 2-(2-(((3,5-bis((nitrooxy)methyl)phenyl)methyl)oxycarbonyl) 2-oxoethylthio) 1-(methoxycarbonyl)ethyl)carbamoyl)(2S) 2-aminobutanoic acid;

methyl (2R)-2-(acetylamino)-3-((3-((2-(nitrooxy)ethoxy)ethyl)amino)-2,3-dioxopropyl)thio) propanoate;

methyl (2R)-2-(acetylamino)-3-((3-((3-(nitrooxy)propyl)amino)-2,3-dioxopropyl)thio) propanoate;

2-(4-(2-(nitrooxy)ethoxy)phenoxy)ethyl 3-((2R)-2-(acetylamino)-2-(methoxycarbonyl) ethylthio)-2-oxopropanoate;

methyl (2R)-2-(acetylamino)-3-((3-((2,2-dimethyl-3-(nitrooxy)propyl)amino)-2,3-dioxopropyl)thio)propanoate;

methyl (2R)-2-(acetylamino)-3-((3-((nitrooxy)methyl)benzyl)oxy)-2,3-dioxopropyl)thio) propanoate;

methyl-(2R) 2-(acetylamino) 3-((3-((2-(nitrooxy)-1-((nitrooxy)methyl)ethyl)amino) 2,3-dioxopropyl)thio)propanoate;

methyl (2*R*)-2-(acetylamino)-3-((3-((4-((nitrooxy)methyl)benzyl)oxy)-2,3-dioxopropyl)thio) propanoate;

2,2-bis((nitrooxy)methyl)-3-(nitrooxy)propyl-3-((2R)-2-(acetylamino)-2-(methoxycarbonyl) ethylthio)-2-oxopropanoate;

2 methyl 3 (nitrooxy) 2 ((nitrooxy)methyl)propyl 3 ((2R) 2 (acetylamino) 2 (methoxycarbonyl) ethylthio) 2 oxopropanoate;

methyl (2R) 2 (acetylamino) 3 ((3 (nitrooxy) 2 ((nitrooxy) methyl)propoxy) 2,3 dioxopropyl) thio)propanoate;

methyl (2R) 2 (acetylamino) 3 - ((3 - (2 - nitro - 3 - (nitrooxy) - 2 - ((nitrooxy) methyl)propoxy) - 2,3 - dioxopropyl)thio)propanoate;

methyl (2R)-2-(acetylamino)-3-((3-(2-(nitrooxy)-1-((nitrooxy)methyl)ethoxy)-2,3-dioxopropyl) thio)propanoate;

methyl (2*R*)-2-(acetylamino)-3-((3-(3-(nitrooxy)propoxy)-2,3-dioxopropyl)thio)propanoate; (3,5-bis((nitrooxy)methyl)phenyl)methyl 3 ((2*R*)-2-(acetylamino)-2-(methoxycarbonyl) ethylthio)-2-oxopropanoate;

methyl (2*R*)-2-(acetylamino)-3-((3-(2,2-dimethyl-3-(nitrooxy)propoxy)-2,3-dioxopropyl) thio)propanoate;

4-((2-(((2R) 2,3-bis(nitrooxy)propyl)oxycarbonyl)(2S) 2-(2-oxopropanoylamino)ethyl) oxycarbonyl)(2S) 2-aminobutanoic acid;

(2S)-4-(((2S)-2-(((2S)-2,3-bis(nitrooxy)propyl)oxycarbonyl)-2-(2-oxopropanoylamino)ethyl) oxycarbonyl)-2-aminobutanoic acid;

Application No. 10/581,340 Amendment dated March 20, 2009 Reply to Office Action of December 23, 2008

- 4-(N-(4-(((2R)-2,3-bis(nitrooxy)propyl)oxycarbonyl)(4S)-4-(2-oxopropanoylamino)butyl) carbamoyl)(2S)-2-aminobutanoic acid;
- (2S) 4 (N ((4S) 4 (((2S) 2,3 bis(nitrooxy)propyl)oxycarbonyl) 4 (2 oxopropanoylamino)butyl) carbamoyl)-2-aminobutanoic acid;
- 4-(N-(5-(((2R)-2,3-bis(nitrooxy)propyl)oxycarbonyl)(5S)-5-(2-oxopropanoylamino) pentyl)carbamoyl)(2S)-2-aminobutanoic acid;
- (2S) 4-(N-((5S) 5-(((2S) 2,3-bis(nitrooxy)propyl)oxycarbonyl) 5-(2-oxopropanoylamino)pentyl) carbamoyl) 2-aminobutanoic acid;
- 5-((2R)-2-(((2R)-2,3-bis(nitrooxy)propyl)oxycarbonyl)-2-(2-oxopropanoylamino)ethylthio)(2S)-2-amino-5-oxopentanoic acid;
- 5-((2R)-2-(((2S)-2,3-bis(nitrooxy)propyl)oxycarbonyl)-2-(2-oxopropanoylamino)ethylthio)(2S)-2-amino-5-oxopentanoic acid;
- 4-(N-(5-(N-((2R)-2,3-bis(nitrooxy)propyl)carbamoyl)(5S)-5-(2-oxopropanoylamino)pentyl) earbamoyl)(2S)-2-aminobutanoic acid;
- (2S)-4-(N-((5S)-5-(N-((2S)-2,3-bis(nitrooxy)propyl)carbamoyl)-5-(2-oxopropanoylamino)pentyl) carbamoyl)-2-aminobutanoic acid;
- (2S) 4 (N-((5S) 5 ((2,2-bis((nitrooxy)methyl) 3 (nitrooxy)propyl)oxycarbonyl) 5 (2-oxopropanoylamino)pentyl)carbamoyl) 2-aminobutanoic acid:
- (2S)-4-(N-((5S)-5-(((6S, 2R)-6-(nitrooxy)-4,8-dioxabicyclo(3.3.0)oct-2-yl)oxycarbonyl)-5-(2-oxopropanoylamino)pentyl)carbamoyl)-2-aminobutanoic acid;
- (2S)-4-(N-((5S)-5-(((2S, 6R)-6-(nitrooxy)-4,8-dioxabicyclo(3.3.0)oct-2-yl)oxycarbonyl)-5-(2-oxopropanoylamino)pentyl)carbamoyl)-2-aminobutanoic acid;
- 4-(((1E) 2 (N-((2R) 2,3-bis(nitrooxy)propyl)carbamoyl)-1-azaprop-1-enyl)oxycarbonyl)(2S)-2-aminobutanoic acid;
- 4-(((1E)-2-(N-((2S)-2,3-bis(nitrooxy)propyl)carbamoyl)-1-azaprop-1-enyl)oxycarbonyl)(2S)-2-aminobutanoic acid;
- 4-(N-((1E) 2-(N-((2R) 2,3-bis(nitrooxy)propyl)carbamoyl) 1-azaprop 1-enyl)carbamoyl)(2S) 2-aminobutanoic acid;

Reply to Office Action of December 23, 2008

4-(N-((1E) 2-(N-((2S) 2,3-bis(nitrooxy)propyl)carbamoyl) 1-azaprop 1-enyl)carbamoyl)(2S) 2-aminobutanoic acid;

4-(N-(1-(((2R)-2,3-bis(nitrooxy)propyl)oxycarbonyl)(1S)-5-(2-oxopropanoylamino)pentyl) carbamoyl)(2S)-2-aminobutanoic acid;

(2S)-4-(N-((1S)-1-(((2S)-2,3-bis(nitrooxy)propyl)oxycarbonyl)-5-(2-oxopropanoylamino)pentyl) carbamoyl)-2-aminobutanoic acid;

4-(N-(1-(N-((2R)-2,3-bis(nitrooxy)propyl)carbamoyl)(1S)-5-(2-oxopropanoylamino)pentyl) carbamoyl)(2S)-2-aminobutanoic acid;

(2S)-4-(N-((1S)-1-(N-((2S)-2,3-bis(nitrooxy)propyl)carbamoyl)-5-(2-oxopropanoylamino)pentyl) carbamoyl) 2-aminobutanoic acid;

4-(N-(1-(((2R)-2,3-bis(nitrooxy)propyl)oxycarbonyl)(1S)-2-(2-oxopropanoyloxy)ethyl) carbamoyl)(2S)-2-aminobutanoic acid;

(2S) 4 (N ((1S) 1 (((2S) 2,3 bis(nitrooxy)propyl)oxyearbonyl) 2 (2 oxopropanoyloxy)ethyl) earbamoyl) 2-aminobutanoic acid;

4-(N-(1-(((2R)-2,3-bis(nitrooxy)propyl)oxycarbonyl)(1S)-4-(2-oxopropanoylamino) butyl)carbamoyl)(2S)-2-aminobutanoic acid;

(2S) 4-(N-((1S)-1-(((2S)-2,3-bis(nitrooxy)propyl)oxycarbonyl) 4-(2-oxopropanoylamino) butyl)carbamoyl) 2-aminobutanoic acid; or a pharmaceutically acceptable salt thereof.